Progress in the clinical development of CX-2051, targeted at advanced colorectal cancer, with initial Phase 1a clinical data expected in the first half of 2025. CytomX maintains a strong financial ...

CytomX Therapeutics has updated its pipeline priorities for 2025, highlighting its lead program, CX-2051, a first-in-class PROBODY ADC targeting EpCAM for advanced metastatic colorectal cancer, with ...

In the world of seemingly identical customer experience (CX) programs, differentiation is the unsung hero that can set your company apart from the competition. Kantar asserts in its company blog that ...

Great customer experience means nothing if your team is doing the heavy lifting behind broken systems — and eventually, that breaks too. There is a quiet crisis unfolding within customer experience ...

The Daniel Group, a leader in B2B customer experience, introduces the CX Institute, offering training and coaching to enhance CX programs. Leveraging insights from one million surveys, the initiative ...